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Adulterated Effects of Nitric Oxide–
Generating Donors
Klaus-D. Kröncke1 and Christoph V. Suschek2
Impaired cutaneous nitric oxide (NO) production is associated with diminished 
antioxidative capacity in skin cells, hindered wound healing, unbalanced inflam-
matory reactions, and disturbed immunological responses. Use of topically 
applied NO donors might represent an auspicious new therapeutic approach in 
the field of dermatology. But what is the appropriate NO–generating compound 
or system? In this issue, Mowbray et al. describe a new chemical inert NO donor 
that per se produces little inflammation in the skin.
Journal of Investigative Dermatology (2008), 128, 258–260. doi:10.1038/sj.jid.5701162
NO is synthesized endogenously by NO 
synthases (NOS), an enzyme family con-
sisting of three members: constitutively 
expressed neuronal NOS, endothelial 
NOS (eNOS), and a cytokine-inducible 
isoform (iNOS). Several lines of evidence 
indicate that NO is involved in several 
physiologic and pathophysiologic reac-
tions in skin, e.g., hair growth, prolif-
eration and differentiation of epidermal 
cells, wound-healing processes, micro-
bicidal activities, antigen presentation, 
allergic skin manifestations, regulation 
of innate immune reactions, and inflam-
matory responses. In addition, NO 
also affects ultraviolet (UV) radiation-
induced processes, such as melanogen-
esis and erythema and edema formation. 
Furthermore, NO is an effective inhibitor 
of lipid peroxidation, and the coordi-
nated action of NO on the expression of 
cell-protecting genes as well as preserva-
tion of membrane function may play an 
important role in the protection against 
UVA- or reactive oxygen species–
induced apoptotic or necrotic cell death 
(for review see Suschek et al., 2006).
In human skin NOS-dependent pro-
duction of NO potentially occurs in all 
cell types by at least one of the three 
NO synthases. Because NO is a radical, 
its sphere of influence is limited to sev-
eral cell diameters. Thus, NO is a local 
mediator that does not need complex 
metabolism for clearance; it is simply 
diluted and then oxidized to nitrite and 
nitrate over time. Storage pools for NO 
do exist: S-nitrosothiols, N-nitroso com-
pounds, and nitrite are among the most 
important. This is of particular signifi-
cance because, during challenge of nor-
mal human skin with environmentally 
relevant UVA doses, nitrite and nitroso 
compounds decompose and form NO, 
enzyme independently, reaching con-
siderably higher concentrations than are 
found with maximal iNOS activity in 
cytokine-activated human keratinocyte 
cultures in vitro. These findings show 
that human skin biology uses naturally 
occurring NO donor molecules, which 
during sunlight exposure may lead to 
non-enzyme-derived high-output NO 
formation. Furthermore, in the acidic 
milieu of human skin, acid-induced 
decomposition of nitrite represents an 
additional source of nonenzymatic cuta-
neous NO production (for review see 
Suschek et al., 2006). Pharmacologic 
intervention with nitrite-derived high-
output NO after acidification appeared 
to be a promising treatment for condi-
tions such as infectious diseases of the 
skin or the vasoconstriction of Raynaud’s 
disease, in which significant vasodilata-
tion has been demonstrated using this 
NO donor system (Tucker et al., 1999). 
However, topical application of acidi-
fied nitrite has been found to induce an 
intense cutaneous inflammatory infil-
trate (Ormerod et al., 1999). Together 
with the finding that iNOS is expressed 
in many inflammatory diseases, includ-
ing a number of inflammatory dermato-
ses, the far-reaching paradigm of NO as 
a strong pro-inflammatory mediator in 
human skin has been established.
NO donors have a wide range of 
potential uses in skin. Benefits of topi-
cally applied NO have been demonstrat-
ed in Raynaud’s syndrome, and other 
conditions that involve diminished skin 
blood flow, such as poorly vascularized 
skin grafts, could also benefit. An excit-
ing prospect is the potential to acceler-
ate wound healing, which is delayed in 
both iNOS- and eNOS-knockout mice. 
In addition, poor wound healing in dia-
betic mice is associated with decreased 
eNOS protein expression as well as 
decreased NO synthesis (for review see 
Weller, 2003). Even a small acceleration 
in wound healing would be significant, 
and data from animal studies are highly 
suggestive that NO-based therapies may 
be worthy candidates for clinical stud-
ies. However, the effects of NO derived 
from NO donors depend on localization 
and the kinetics of release. High-output 
bursts of NO, such as those released by 
the chemical reduction of nitrite, may 
be ideal for their microbicidal effects but 
not necessarily for other purposes.
The ubiquity of NO in mammalian 
physiology, although promising for many 
pharmacologic benefits, is at the same 
time an Achilles heel. The two major 
practical problems are lack of specific-
ity, which may result in unwanted side 
effects, and the lack of adequate phar-
macokinetically appropriate and local-
ized means of NO delivery. A wide range 
of NO donors with different modes and 
rates of NO release are on the market 
that release NO either spontaneously 
or after enzymatic conversion. NO 
donor drugs can be tailor-made to suit 
a particular disease target. Long-term 
use of most clinically used NO donors, 
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Nitric oxide may be 
released in skin from 
bound complexes 
with hydrated 
aluminosilicates.
however, is often limited by tolerance 
and toxicity issues, ensuring the need for 
novel alternatives (for review see Miller 
and Megson, 2007).
In the 1960s the American chemist 
Russell Drago synthesized and character-
ized several adducts of NO with second-
ary amines and called them NONOates, 
now known as diazeniumdiolates. The 
advantage of this class of NO donors is 
that they can be tailored to release NO 
within seconds, minutes, hours, or even 
days (for review see Keefer, 2005). These 
polyamine NO adducts have proved 
extremely popular in the experimen-
tal setting because of their predictable 
NO release. NONOates have been 
employed successfully in a number of 
cardiovascular disorders and diseases, 
especially when slow, prolonged release 
is desired, and there is great interest in 
promoting tumor regression by deliver-
ing cytotoxic levels of NO to cancer 
cells via NONOates. Therefore, a series 
of NONOates has been designed with 
protected diolate groups that release 
NO upon specific enzymatic reactions 
in tumor cells. However, because many 
polyamines are corrosive, the poten-
tial toxicity of the parent compound 
and by-products of NONOate metabo-
lism remains to be investigated before 
topical application of these compounds 
can be considered. S-nitrosothiols are 
another group of NO donors that can be 
designed to release NO at varying rates. 
They decompose cleanly with release 
of NO and formation of the respective 
disulfide. S-nitrosothiols occur naturally 
in blood plasma (e.g., as S-nitrosogluta-
thione), may play some part in the nor-
mal metabolism of NO, and may act 
as NO storage compounds. Alterations 
in the structure of S-nitrosothiols to 
modify lipophilicity may allow these 
compounds to target areas of interest, 
minimizing their side effects. Polymeric 
materials containing S-nitrosothiols hold 
a great deal of promise as coatings for 
stents, extracorporeal circuits, and cath-
eters used in interventional cardiological 
procedures, surgery, and renal replace-
ment therapy. In recent years many 
new hybrid NO donor drugs have been 
developed. The concept behind them is 
best described as NO-donating nonste-
roidal anti-inflammatory drugs. These 
compounds retain the actions of their 
parent compounds (analgesia, inhibition 
of inflammation, decreased thrombosis) 
but have additional beneficial actions 
attributed to NO, e.g., protecting against 
gastric damage caused by aspirin. The 
concept has been extended to a vast 
array of pharmacologic agents such as 
anticoagulants, antitumor agents, ion 
channel inhibitors, angiotensin-convert-
ing enzyme inhibitors, and histamine 
receptor inhibitors (for review see Miller 
and Megson, 2007). It remains to be 
seen whether any of these agents can be 
used to treat skin diseases or disorders. 
With conventional NO donors, a spon-
taneous or induced decomposition leads 
not only to release of the NO radical but 
also to the formation of more or less bio-
active parent compound(s) or additional 
chemically reactive species (Scatena et 
al., 2005).
For example, one concern about the 
clinical use of NONOates is simulta-
neous release of the secondary amine. 
Because NO in an oxygen-rich environ-
ment can readily form nitrosating spe-
cies (probably N2O3), formation of car-
cinogenic secondary nitrosamines may 
occur. Additionally, polyamines per se 
might exhibit significant biologic effects 
that support or counteract the beneficial 
effects of NO. With respect to S-nitroso-
thiols, if the parent compound is a natu-
rally occurring molecule, these compo-
nents are without hazard. Unfortunately, 
the most simple one, S-nitrosocyste-
ine, is quite unstable. Therefore, much 
experimental research has been carried 
out using S-nitroso-N-acetylpenicilla-
mine; however, the parent compound 
N-acetylpenicillamine is an antibiotic. 
Even physiologically occurring thiols 
are not biologically inert. Glutathione 
disulfide, obtained after decomposition 
of S-nitrosoglutathione, may be reduced 
enzymatically to glutathione, which is 
an important redox-active compound 
that may support the protective proper-
ties of NO. On the other hand, sulfur-
centered glutathiyl radicals have been 
shown to promote the oxidation of phos-
pholipids in living cells and to cause cell 
death. Photo-induced decomposition of 
nitrite results in NO generation, but also 
in the generation of hydroxyl and nitro-
gen dioxide radicals, both of which are 
highly toxic compounds (for review see 
Suschek et al., 2006).
Among the topically applied NO 
donors are polyethyleneimine cellulose 
NONOates (Shabani et al., 1996) and 
S-nitrosothiols such as S-nitrosated thio-
monosaccharides (Khan et al., 2003), 
low-molecular-weight S-nitrosothiols 
embedded in a hydrogel (Seabra et al., 
2004), and poly-S-nitrosated polyesters 
(Seabra et al., 2005). In animal models, 
NO gas has been used to treat wounds 
(Shekhter et al., 2005) and skin infec-
tions (Ghaffari et al., 2007). However, 
NO gas is notoriously difficult to handle 
with respect to complete exclusion of 
oxygen to prevent oxidation to nitro-
gen dioxide. In this issue of Journal of 
Investigative Dermatology Mowbray 
et al. (2008) report that application of 
pure NO in a controlled manner per se 
produces little inflammation in human 
skin. This is in contrast to the inflamma-
tory effects resulting from use of a cream 
containing an acidic mixture of ascorbic 
acid and nitrite. In a novel approach to 
storing and delivering NO to the skin, 
the authors used zeolites, hydrated alu-
minosilicates with an open structure 
(“molecular sieves”) that can accommo-
date a wide variety of cations. Exposure 
of these solids to NO gas results in NO 
binding to the metal ions within the 
pores, facilitating highly efficient pack-
ing of NO. NO-zeolites of this type 
are very stable in the anhydrous state, 
but NO is displaced when they con-
tact water. The beauty of zeolites is that 
chemically they are completely inert, 
they constitute very-high-capacity stores 
for NO, and their rate of release can be 
modulated by altering the chemical zeo-
lite composition (Wheatley et al., 2006). 
The infinite flexibility of NO release 
allows the development of a wide range 
of different NO donor materials for pur-
poses ranging from fast-acting antimi-
crobial coatings for urinary catheters 
and wound dressings to durable, slow-
acting antithrombotic coatings for stents, 
bypass tubing, cannulae, and catheters. 
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Although still in an early stage, this 
approach represents a novel and simple 
way to optimize the benefits of topical 
NO as a local biologic mediator.
Although NO-releasing zeolites may 
not be the last answer, it is to the credit of 
Mowbray et al. that they have designed 
a system of applying pure NO in a con-
trolled and predictable manner without 
causing an inflammatory reaction in 
human skin. Wound healing is a partic-
ularly interesting application, given the 
multiple benefits that NO might have, 
depending on its concentration and the 
kinetics of delivery. Central to the suc-
cess of NO donor therapy is generation 
of the correct amount of NO in the right 
place for the right length of time. Solving 
these problems will undoubtedly lead to 
new NO donor therapies for skin diseas-
es and disorders.
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Neuroimmune Communication in 
Skin: Far from Peripheral
Sven Hendrix1
The precise nature of the link between stress and exacerbation of skin inflam-
mation has puzzled researchers and clinicians alike. The traditional expla-
nation is that immune balance is altered by activation of two stress axes: 
activation of the hypothalamic–pituitary–adrenal (HPA) axis raises cortisol lev-
els, and activation of the sympathetic nervous systems raises adrenaline levels 
(Figure 1). In this issue, Pavlovic et al. (2008) provide evidence for a third stress 
axis and report that stress travels to the skin through peripheral neuropeptider-
gic nerve fibers and exacerbates the neurogenic inflammatory aspect of cuta-
neous dermatitis. Clarification of the role of this alternative stress axis may 
enable the design of novel therapeutic strategies.
Journal of Investigative Dermatology (2008), 128, 260–261. doi:10.1038/sj.jid.5701171
Pathologies that involve chronic 
relapse and significant discomfort, 
such as atopic dermatitis, are regarded 
as psychosomatic dermatoses (Wright 
et al., 2005). In the early days of psy-
choanalysis, the skin was regarded as 
one vehicle by which the body and 
soul express the feelings and well-
being of its bearer. Itchy and inflamed 
skin was interpreted as a cry for atten-
tion and help and a sign of severe 
deprivation of tenderness and care.
In the past, the close interaction 
between neuropeptidergic nerve fibers 
and immune cells in the skin was 
widely understood as playing a role in 
the cutaneous stress response. Altered 
nerve-fiber counts in atopic dermatitis, 
psoriasis, nummular eczema, and many 
other—mostly chronic and inflamma-
tory—skin pathologies were viewed as 
evidence of the possible influence of 
stress on the course of inflammation.
In parallel, stress research pro-
vided evidence of a close interaction 
between nerve fibers and, for exam-
ple, mast cells under stress (rang-
ing from physical to psychological) 
(Theoharides and Cochrane, 2004). 
The idea that mast cells are activated 
under conditions of stress in exac-
erbated inflammatory skin disease 
became accepted almost to the point 
of textbook knowledge, even though 
experimental evidence has still not 
been provided.
Initial insights into the pathogen-
esis of stress-induced exacerbation of 
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